Depomed Inc. (NASDAQ:DEPO) traded down 1.9% on Thursday . The stock traded as low as $20.17 and last traded at $20.29, with a volume of 391,507 shares. The stock had previously closed at $20.69.

Several equities research analysts recently weighed in on the stock. Cantor Fitzgerald reaffirmed a “buy” rating on shares of Depomed in a research report on Thursday, August 11th. Piper Jaffray Cos. reaffirmed a “neutral” rating and set a $19.00 price objective (up previously from $18.00) on shares of Depomed in a research report on Thursday, August 4th. Mizuho boosted their target price on Depomed from $19.00 to $23.00 and gave the stock a “buy” rating in a research note on Friday, May 27th. Janney Montgomery Scott boosted their target price on Depomed from $20.13 to $28.00 and gave the stock a “hold” rating in a research note on Thursday, May 26th. Finally, JMP Securities lowered their target price on Depomed from $28.00 to $22.00 and set a “market outperform” rating for the company in a research note on Thursday, August 4th. One analyst has rated the stock with a sell rating, four have given a hold rating and eight have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $22.65.

The stock’s 50-day moving average is $19.89 and its 200-day moving average is $17.90. The stock’s market capitalization is $1.21 billion.

Depomed (NASDAQ:DEPO) last announced its quarterly earnings results on Wednesday, August 3rd. The specialty pharmaceutical company reported $0.27 EPS for the quarter, topping the Zacks’ consensus estimate of $0.26 by $0.01. The company earned $116.70 million during the quarter, compared to analysts’ expectations of $118.20 million. During the same period last year, the firm earned $0.27 earnings per share. Depomed’s revenue for the quarter was up 23.5% on a year-over-year basis. On average, analysts expect that Depomed Inc. will post $1.21 EPS for the current fiscal year.

In other Depomed news, VP Thadd M. Vargas sold 26,290 shares of Depomed stock in a transaction that occurred on Wednesday, August 10th. The stock was sold at an average price of $20.92, for a total value of $549,986.80. Following the transaction, the vice president now directly owns 84,336 shares of the company’s stock, valued at approximately $1,764,309.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO August J. Moretti sold 5,000 shares of Depomed stock in a transaction that occurred on Wednesday, August 10th. The stock was sold at an average price of $21.40, for a total value of $107,000.00. The disclosure for this sale can be found here.

An institutional investor recently raised its position in Depomed stock. US Bancorp DE increased its position in Depomed Inc. (NASDAQ:DEPO) by 106.9% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 55,393 shares of the specialty pharmaceutical company’s stock after buying an additional 28,622 shares during the period. US Bancorp DE owned about 0.09% of Depomed worth $1,004,000 at the end of the most recent quarter.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.